Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors

Giuseppe Procopio, Monica Niger, Isabella Testa

Research output: Contribution to journalArticle

Abstract

Chemotherapy-induced febrile neutropenia (FN) is a major risk factor for severe infections potentially fatal, and also a dose-limiting toxicity, so causing dose reductions and/or delays in scheduled chemotherapy. This lecture provides recommendations for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. If expected risk of FN is equal or superior to 20%, a primary prophylaxis of FN with G-CSF is recommended. Primary prophylaxis can be considered in case of intermediate 10-20% risk of FN, in presence of factors that increase the frequency/risk of FN, such as age >65, advanced disease, prior episode of FN, poor performance status, radiotherapy to a wide body area (>20%). In case of low risk of FN (

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalNeurological Sciences
DOIs
Publication statusAccepted/In press - 2011

Fingerprint

Chemotherapy-Induced Febrile Neutropenia
Colony-Stimulating Factors
Febrile Neutropenia
Guidelines
Granulocyte Colony-Stimulating Factor
Radiotherapy
Drug Therapy

Keywords

  • Chemotherapy-induced febrile neutropenia
  • Colony stimulating factors
  • Guidelines

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology
  • Dermatology

Cite this

Lecture : management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors. / Procopio, Giuseppe; Niger, Monica; Testa, Isabella.

In: Neurological Sciences, 2011, p. 1-3.

Research output: Contribution to journalArticle

@article{5b4cd6282c5047b9b06db7ca9ac50ce5,
title = "Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors",
abstract = "Chemotherapy-induced febrile neutropenia (FN) is a major risk factor for severe infections potentially fatal, and also a dose-limiting toxicity, so causing dose reductions and/or delays in scheduled chemotherapy. This lecture provides recommendations for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. If expected risk of FN is equal or superior to 20{\%}, a primary prophylaxis of FN with G-CSF is recommended. Primary prophylaxis can be considered in case of intermediate 10-20{\%} risk of FN, in presence of factors that increase the frequency/risk of FN, such as age >65, advanced disease, prior episode of FN, poor performance status, radiotherapy to a wide body area (>20{\%}). In case of low risk of FN (",
keywords = "Chemotherapy-induced febrile neutropenia, Colony stimulating factors, Guidelines",
author = "Giuseppe Procopio and Monica Niger and Isabella Testa",
year = "2011",
doi = "10.1007/s10072-011-0795-x",
language = "English",
pages = "1--3",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",

}

TY - JOUR

T1 - Lecture

T2 - management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors

AU - Procopio, Giuseppe

AU - Niger, Monica

AU - Testa, Isabella

PY - 2011

Y1 - 2011

N2 - Chemotherapy-induced febrile neutropenia (FN) is a major risk factor for severe infections potentially fatal, and also a dose-limiting toxicity, so causing dose reductions and/or delays in scheduled chemotherapy. This lecture provides recommendations for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. If expected risk of FN is equal or superior to 20%, a primary prophylaxis of FN with G-CSF is recommended. Primary prophylaxis can be considered in case of intermediate 10-20% risk of FN, in presence of factors that increase the frequency/risk of FN, such as age >65, advanced disease, prior episode of FN, poor performance status, radiotherapy to a wide body area (>20%). In case of low risk of FN (

AB - Chemotherapy-induced febrile neutropenia (FN) is a major risk factor for severe infections potentially fatal, and also a dose-limiting toxicity, so causing dose reductions and/or delays in scheduled chemotherapy. This lecture provides recommendations for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. If expected risk of FN is equal or superior to 20%, a primary prophylaxis of FN with G-CSF is recommended. Primary prophylaxis can be considered in case of intermediate 10-20% risk of FN, in presence of factors that increase the frequency/risk of FN, such as age >65, advanced disease, prior episode of FN, poor performance status, radiotherapy to a wide body area (>20%). In case of low risk of FN (

KW - Chemotherapy-induced febrile neutropenia

KW - Colony stimulating factors

KW - Guidelines

UR - http://www.scopus.com/inward/record.url?scp=80053901363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053901363&partnerID=8YFLogxK

U2 - 10.1007/s10072-011-0795-x

DO - 10.1007/s10072-011-0795-x

M3 - Article

SP - 1

EP - 3

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

ER -